← Product Code [OZN](/submissions/MI/subpart-d%E2%80%94serological-reagents/OZN) · K210385

# cobas Cdiff nucleic acid test for use on the cobas Liat System (K210385)

_Roche Molecular Systems, Inc. · OZN · Sep 9, 2021 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZN/K210385

## Device Facts

- **Applicant:** Roche Molecular Systems, Inc.
- **Product Code:** [OZN](/submissions/MI/subpart-d%E2%80%94serological-reagents/OZN.md)
- **Decision Date:** Sep 9, 2021
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 866.3130
- **Device Class:** Class 2
- **Review Panel:** Microbiology

## Indications for Use

The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridioides difficile (C.difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.

## Device Story

The cobas Cdiff test is a rapid, automated in vitro diagnostic assay for qualitative detection of C. difficile toxin B (tcdB) DNA in human stool. The system uses a closed, self-contained assay tube containing pre-packed reagents. The cobas Liat Analyzer performs automated nucleic acid extraction via silica magnetic particles, target enrichment, inhibitor removal, and real-time PCR amplification. The analyzer uses actuators to compress the assay tube, moving samples and reagents through segments to control reaction conditions (temperature, pressure, volume). The system provides automated result interpretation displayed on an integrated LCD touch screen. Used in clinical settings to aid CDI diagnosis; results assist healthcare providers in clinical decision-making. The closed-tube design minimizes cross-contamination risk.

## Clinical Evidence

No clinical data provided. The submission relies on design control activities, risk analysis, and verification/validation of software modifications to demonstrate substantial equivalence.

## Technological Characteristics

Nucleic acid amplification assay for Clostridioides difficile toxin genes. The device operates on the cobas Liat System. Modification involves software updates only. Fundamental scientific technology remains consistent with the predicate device.

## Regulatory Identification

A Clostridium difficile toxin gene amplification assay is a device that consists of reagents for the amplification and detection of target sequences in Clostridium difficile toxin genes in fecal specimens from patients suspected of having Clostridium difficile infection (CDI). The detection of clostridial toxin genes, in conjunction with other laboratory tests, aids in the clinical laboratory diagnosis of CDI caused by Clostridium difficile.

## Special Controls

In combination with the general controls of the FD&C Act, the Portrait Toxigenic C. difficile Assay is subject to the following special controls: 1. The special controls for the Clostridium difficile toxin gene amplification assay are contained in the guidance document: "Class II Special Controls Guidance Document: Toxin Gene Amplification Assays for the Detection of Clostridium difficile."

*Classification.* Class II (special controls). The special controls are set forth in FDA's guideline document entitled: “Class II Special Controls Guideline: Toxin Gene Amplification Assays for the Detection of*Clostridium difficile;* Guideline for Industry and Food and Drug Administration Staff.” See § 866.1(e) for information on obtaining this document.

## Predicate Devices

- cobas® Cdiff Nucleic Acid Test for use on the cobas® Liat® System ([K171770](/device/K171770.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

# SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

## I Background Information:

A 510(k) Number

K210385

B Applicant

Roche Molecular Systems, Inc.

C Proprietary and Established Names

cobas Cdiff Nucleic acid test for use on the cobas Liat System

D Regulatory Information

1. Regulation section:
21 CFR 866.3130, *Clostridioides difficile* toxin gene amplification assay

2. Classification:
II

3. Product code:
OZN, OOI

4. Panel:
Microbiology (83)

## II Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II devices requiring 510(k). The following items are present and acceptable.

1. The name and 510(k) number of the SUBMITTER'S previously cleared device.

2. Submitter's statement that the INDICATIONS FOR USE/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).

3. A description of the device **MODIFICATION(S)**, including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the **FUNDAMENTAL SCIENTIFIC TECHNOLOGY** of the modified device has not changed. This change was for software updates only.

4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.

5. A Design Control Activities Summary which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.

b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.

The labeling for the modified subject devices have been reviewed to verify that the indication/intended use for the devices are unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the devices be determined substantially equivalent to the previously cleared devices.

K200065 - Page 2 of 2

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZN/K210385](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZN/K210385)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com